BSN CAPITAL PARTNERS Ltd Invests $43.09 Million in Intuitive Surgical, Inc. $ISRG

Key Points

• BSN CAPITAL PARTNERS Ltd acquired a new position in Intuitive Surgical by purchasing 87,000 shares valued at approximately $43.09 million, making it the firm's 8th largest investment.
• Intuitive Surgical's recent quarterly earnings surpassed expectations, with $2.19 earnings per share (EPS) and revenue of $2.44 billion, showing a year-over-year revenue increase of 21.4%.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Intuitive Surgical, with an average price target of $595.95, indicating optimism for the company's future growth.

BSN CAPITAL PARTNERS Ltd purchased a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 87,000 shares of the medical equipment provider's stock, valued at approximately $43,088,000. Intuitive Surgical accounts for 2.1% of BSN CAPITAL PARTNERS Ltd's holdings, making the stock its 8th largest position.

Several other institutional investors also recently added to or reduced their stakes in ISRG. Chilton Capital Management LLC increased its position in Intuitive Surgical by 614.3% in the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after buying an additional 43 shares during the period. Parvin Asset Management LLC bought a new position in Intuitive Surgical in the 4th quarter worth approximately $26,000. Global Financial Private Client LLC increased its position in Intuitive Surgical by 253.3% in the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after buying an additional 38 shares during the period. Elite Financial Inc. bought a new position in Intuitive Surgical in the 1st quarter worth approximately $26,000. Finally, LFA Lugano Financial Advisors SA bought a new position in Intuitive Surgical in the 1st quarter worth approximately $30,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Trading Up 1.3%

ISRG stock traded up $6.28 during trading on Friday, hitting $476.16. The company had a trading volume of 2,023,902 shares, compared to its average volume of 1,973,062. The company has a fifty day moving average price of $504.42 and a two-hundred day moving average price of $522.06. The company has a market cap of $170.69 billion, a P/E ratio of 66.41, a P/E/G ratio of 4.92 and a beta of 1.59. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.Intuitive Surgical's quarterly revenue was up 21.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.78 EPS. On average, analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of Intuitive Surgical stock in a transaction on Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. The trade was a 92.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction on Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the transaction, the senior vice president owned 907 shares of the company's stock, valued at approximately $510,740.77. The trade was a 19.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,839 shares of company stock valued at $7,896,972 in the last 90 days. 0.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on ISRG. Deutsche Bank Aktiengesellschaft downgraded Intuitive Surgical from a "hold" rating to a "sell" rating and dropped their price target for the stock from $515.00 to $440.00 in a research report on Monday, June 9th. UBS Group lifted their price objective on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Wells Fargo & Company lifted their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a report on Wednesday, July 23rd. Zacks Research lowered Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a report on Wednesday. Finally, BTIG Research lifted their price objective on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.